Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level

Table 7 Influence of different risk factors on mortality after post-transplant lymphoproliferative disorder

	Alive patient	Deceased patient	P value
All PTLD patients
Sex			0.491
Male	10	13
Female	13	7
Multi-organ involvement			0.001
(+)	6	12
(-)	26	6
CMV status			0.284
CMV-positive	9	4
CMV-negative	6	6
EBV status			0.042
EBV-positive	13	4
EBV-negative	3	6
Rejection episode			0.600
(+)	15	9
(-)	18	11
Type of allograft			0.485
Living donor	18	10
Deceased donor	15	10
Pediatric PTLD patients
Sex			0.424
Male	13	10
Female	11	6
Multi-organ involvement			0.001
(+)	5	11
(-)	19	3
CMV status			0.110
CMV-positive	9	3
CMV-negative	4	6
EBV status			0.018
EBV-positive	13	4
EBV-negative	1	5
Rejection episode			0.525
(+)	11	8
(-)	13	8
Type of allograft			0.309
Living donor	18	10
Deceased donor	6	6

CMV: Cytomegalovirus; EBV: Epstein-Barr virus; PTLD: Post-transplant lymphoproliferative disorder.